No significant survival benefits reported for perioperative chemoimmunotherapy in resectable G/GEJ cancers
Final results of the KEYNOTE-585 study indicate that the current treatment standard for resectable G/GEJ should remain unchanged
Final results of the KEYNOTE-585 study indicate that the current treatment standard for resectable G/GEJ should remain unchanged
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting
Innovative approaches are investigated to predict cancer development in patients with cirrhosis and detect early recurrence after resection
Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
Recent results from research have changed the treatment paradigm for some digestive tumours, but further evidence is needed to finetune the neoadjuvant approach
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
A study reports high sensitivity and specificity of a cell-free DNA blood-based assay compared to colonoscopy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.